ImmunityBio Shares Gain Momentum on Strong Revenue and Regulatory Progress
Published on 02/02/2026 at 10:29 | Redaktion boerse-global.de
ImmunityBio has entered February with significant operational momentum, driven by surging revenue, greater clarity from U.S. regulators, and initial international approvals for its immunotherapy, ANKTIVA. Following an extremely volatile January that saw shares rally over 190%, investor attention is now shifting to the next regulatory milestone: the potential speed of a planned label expansion in the United States.
The company has reported unaudited preliminary figures for its 2025 fiscal year, revealing net product revenue of approximately $113 million. This represents a staggering increase of 700% compared to the prior year.
Growth accelerated further in the fourth quarter, with revenue reaching $38.3 million. This figure marks a Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
